Clinical Trials
48 trialsNCT06191744 2026-05-06
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT06084936 2026-05-04
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT04384484 2026-04-28
LOTIS 5
ADC Therapeutics S.A.
Phase 3 Active not recruiting
NCT04666038 2026-04-24
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04529772 2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3 Active not recruiting
NCT00006721 2026-03-16
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT06356129 2026-02-12
GOLSEEK-1
Celgene
Phase 3 Active not recruiting
NCT04182204 2025-12-22
POLARGO
Hoffmann-La Roche
Phase 3 Completed
NCT00278408 2025-08-26
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT05409066 2025-07-28
EPCORE FL-1
Genmab
Phase 3 Active not recruiting
NCT01996865 2025-07-10
MAGNIFY
Celgene
Phase 3 Completed
NCT01974440 2025-05-25
SELENE
Janssen Research & Development, LLC
Phase 3 Completed
NCT01855750 2025-02-04
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT00004112 2024-09-23
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
Phase 3 Completed
NCT06573645 2024-08-27
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT00112931 2024-05-09
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
University College, London
Phase 3 Completed
NCT00075946 2024-02-01
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00078949 2023-08-23
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Canadian Cancer Trials Group
Phase 3 Completed
NCT00052936 2021-05-18
Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT00278421 2021-03-11
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
German High-Grade Non-Hodgkin's Lymphoma Study Group
Phase 3 Completed
NCT02165397 2021-03-03
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
Pharmacyclics LLC.
Phase 3 Completed
NCT00004179 2021-02-15
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00004031 2021-02-02
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT00577993 2020-11-16
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00551239 2020-10-19
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
CTI BioPharma
Phase 3 Withdrawn
NCT01889069 2020-08-13
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
Hoffmann-La Roche
Phase 3 Completed
NCT00064116 2020-04-01
IDEC-C2B8
Canadian Cancer Trials Group
Phase 3 Completed
NCT00137995 2019-08-28
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
Lymphoma Study Association
Phase 3 Completed
NCT00003280 2019-05-15
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma
Swiss Cancer Institute
Phase 3 Completed
NCT00227695 2019-05-15
Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma
Swiss Cancer Institute
Phase 3 Completed
NCT01232556 2019-01-08
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Pfizer
Phase 3 Terminated
NCT00135499 2018-08-23
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
Lymphoma Study Association
Phase 3 Terminated
NCT02366663 2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3 Terminated
NCT01659099 2018-03-07
GAINED
The Lymphoma Academic Research Organisation
Phase 3 Terminated
NCT00801281 2017-07-17
PLRG4
Polish Lymphoma Research Group
Phase 3 Completed
NCT00140582 2017-03-13
Primary Rituximab and Maintenance
Lymphoma Study Association
Phase 3 Completed
NCT01609010 2014-09-08
A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
Hoffmann-La Roche
Phase 3 Completed
NCT00324831 2013-12-18
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 3 Suspended
NCT00005589 2013-09-17
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00028717 2013-09-17
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00012051 2013-08-12
Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00089115 2013-08-02
Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00003150 2013-06-21
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00006708 2013-04-10
S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Terminated
NCT00003595 2013-02-08
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT01103388 2012-07-30
Rituximab Maintenance After Autologous Transplantation
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00052923 2009-02-09
Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00136552 2007-07-03
Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden
Lymphoma Study Association
Phase 3 Completed